Generic Name: dinutuximab
Brand Name: Unituxin
Manufacturer: United Therapeutics Corp.
Therapeutic Area: Neuroblastoma (pediatric)
Indications: For the treatment of pediatric patients with relapsed/refractory high-risk neuroblastoma in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor.
Manufacturer Requested Reimbursement Criteria1: To be used in combination with granulocyte macrophage colony-stimulating factor, irinotecan and temozolomide for the treatment of pediatric patients with high-risk neuroblastoma who have relapsed following consolidation treatment, or who did not achieve a durable remission following consolidation treatment.
Submission Type: Initial
Tumour Type: Neurological
Project Status: Received
Companion Diagnostics: No
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||October 22, 2020|
|Call for patient/clinician input closed||December 10, 2020|
|Submission received||November 23, 2020|